TWI342773B - - Google Patents
Download PDFInfo
- Publication number
- TWI342773B TWI342773B TW093128401A TW93128401A TWI342773B TW I342773 B TWI342773 B TW I342773B TW 093128401 A TW093128401 A TW 093128401A TW 93128401 A TW93128401 A TW 93128401A TW I342773 B TWI342773 B TW I342773B
- Authority
- TW
- Taiwan
- Prior art keywords
- acid
- human
- secretion
- defensin
- promoting
- Prior art date
Links
- 230000028327 secretion Effects 0.000 claims description 140
- 108010002069 Defensins Proteins 0.000 claims description 118
- 102000000541 Defensins Human genes 0.000 claims description 117
- 230000001737 promoting effect Effects 0.000 claims description 104
- 150000007524 organic acids Chemical class 0.000 claims description 73
- 239000003795 chemical substances by application Substances 0.000 claims description 60
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 60
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 48
- 210000000214 mouth Anatomy 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 38
- VZCYOOQTPOCHFL-OWOJBTEDSA-N fumaric acid group Chemical group C(\C=C\C(=O)O)(=O)O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 34
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 28
- 235000013305 food Nutrition 0.000 claims description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 25
- 101710178510 Defensin-2 Proteins 0.000 claims description 24
- 239000004480 active ingredient Substances 0.000 claims description 24
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 23
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 22
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 22
- 239000001630 malic acid Substances 0.000 claims description 22
- 235000011090 malic acid Nutrition 0.000 claims description 22
- 235000015165 citric acid Nutrition 0.000 claims description 20
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 19
- 239000011975 tartaric acid Substances 0.000 claims description 18
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 17
- 235000002906 tartaric acid Nutrition 0.000 claims description 17
- 235000011054 acetic acid Nutrition 0.000 claims description 16
- 239000001530 fumaric acid Substances 0.000 claims description 16
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 15
- 235000011087 fumaric acid Nutrition 0.000 claims description 15
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 15
- 239000004310 lactic acid Substances 0.000 claims description 14
- 235000014655 lactic acid Nutrition 0.000 claims description 14
- 239000011668 ascorbic acid Substances 0.000 claims description 12
- 235000010323 ascorbic acid Nutrition 0.000 claims description 12
- 229960005070 ascorbic acid Drugs 0.000 claims description 12
- 239000001361 adipic acid Substances 0.000 claims description 11
- 235000011037 adipic acid Nutrition 0.000 claims description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 8
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 8
- 235000005979 Citrus limon Nutrition 0.000 claims description 8
- 244000131522 Citrus pyriformis Species 0.000 claims description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 8
- 235000013985 cinnamic acid Nutrition 0.000 claims description 8
- 229930016911 cinnamic acid Natural products 0.000 claims description 8
- 239000004220 glutamic acid Substances 0.000 claims description 8
- 235000013922 glutamic acid Nutrition 0.000 claims description 8
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 8
- 239000004575 stone Substances 0.000 claims description 6
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 5
- 230000003248 secreting effect Effects 0.000 claims description 5
- 239000001384 succinic acid Substances 0.000 claims description 5
- 102000044159 Ubiquitin Human genes 0.000 claims description 4
- 108090000848 Ubiquitin Proteins 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 235000011044 succinic acid Nutrition 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- BHUPIKYIGMWGAD-UHFFFAOYSA-N 2-amino-9-(hydroxymethyl)-3-oxophenoxazine-1-carboxylic acid Chemical compound C1=CC=C2OC3=CC(=O)C(N)=C(C(O)=O)C3=NC2=C1CO BHUPIKYIGMWGAD-UHFFFAOYSA-N 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 244000037364 Cinnamomum aromaticum Species 0.000 claims 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims 1
- 244000166124 Eucalyptus globulus Species 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 150000004687 hexahydrates Chemical class 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 description 38
- 238000012360 testing method Methods 0.000 description 17
- 239000003814 drug Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 210000003800 pharynx Anatomy 0.000 description 10
- 238000007429 general method Methods 0.000 description 9
- 229940093915 gynecological organic acid Drugs 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 235000005985 organic acids Nutrition 0.000 description 8
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 102100038326 Beta-defensin 4A Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 235000015218 chewing gum Nutrition 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 208000003322 Coinfection Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 229940112822 chewing gum Drugs 0.000 description 5
- 230000007123 defense Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229960002989 glutamic acid Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- -1 ultraviolet diffuser Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000001680 brushing effect Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000011888 snacks Nutrition 0.000 description 4
- 206010006326 Breath odour Diseases 0.000 description 3
- 101710178508 Defensin 3 Proteins 0.000 description 3
- 102100029790 Defensin-6 Human genes 0.000 description 3
- 101710178511 Defensin-6 Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002826 coolant Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 208000002925 dental caries Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102100021420 Defensin-5 Human genes 0.000 description 2
- 101710178517 Defensin-5 Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 206010014801 endophthalmitis Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 238000002309 gasification Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 2
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-SZSCBOSDSA-N 2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound OC[C@H](O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-SZSCBOSDSA-N 0.000 description 1
- FEWFXBUNENSNBQ-UHFFFAOYSA-N 2-hydroxyacrylic acid Chemical compound OC(=C)C(O)=O FEWFXBUNENSNBQ-UHFFFAOYSA-N 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- WMRXHQRDCIXTCD-UHFFFAOYSA-N 3-hydrazinylpropan-1-ol Chemical compound NNCCCO WMRXHQRDCIXTCD-UHFFFAOYSA-N 0.000 description 1
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010755 Conjunctivitis viral Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 1
- 101710178505 Defensin-1 Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000320368 Eucryphia cordifolia Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000237503 Pectinidae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 208000005914 Viral Conjunctivitis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940065115 grapefruit extract Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000008025 hordeolum Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 102000049262 human DEFB4A Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001057 purple pigment Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- CYHOMWAPJJPNMW-JIGDXULJSA-N tropine Chemical compound C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
- General Preparation And Processing Of Foods (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
1342773 九、發明說明: 【發明所屬之技術領域】 本發明是有關於可促進yS防禦素分泌之沒防禦素分泌促 進劑。又,本發明是有關於促進/5防禦素分泌之方法。 5【先前技術】
從以前就已知,在植物、昆蟲、兩棲類、哺乳類等當中存 在有活體内之抗諸物質(抗菌肽)作為與生俱來之活體防禦機 構,稱之為天然免疫,負責局部區域之感染防禦。在人類身上 已知之抗菌肽之一種之防禦素,對細菌、真菌、原蟲、病毒等 10 具有抗菌活性,而與活體内各種活體防禦機構相關連。
顯現於皮膚、肺、氣管、腎臟、生殖器等黏膜上皮之防禦 素,為人知的有召防禦素。現在,人類/3防禦素已有6種(人 類防禦素-1、人類/5防禦素-2、人類/5防禦素-3、人類/3防 禦素-4、人類/3防禦素-5及人類/3防禦素-6)已被單離且其構 15 造亦已確定。特別是人類/3防禦素-6,已清楚得知其在皮膚、 肺、氣管及口腔黏膜中尤其強烈地顯現出可在細菌感染或炎症 性細胞介素刺激下顯現衍生這種特徵(參考富田哲治等、「作 為活體防禦機構之防禦素」、曰本老年醫學會雜誌、2001年、 第18卷、第4號、第440-443頁),同時有報告指出其與肺炎 20 等氣管感染症或炎症有著密切關係。 又,近年,也有報告指出,/3防禦素不僅關係到局部之感 染防禦,甚至也藉由使樹狀細胞、T淋巴球、單核白血球等細 胞趨化而與後天性免疫有所關聯。(參考Yang, D·,Chertov, 0., Bykovskaia, S.N. et al·,‘‘ /S -Defensins : linking innate and 5 1342773
Adaptive immunity through dendritic and T cell CCR6’,,Science, 1999, vol.286 ' p.525 ; Territo, M.C., Ganz, T., Selsted, M.E. et al” “Monocyto- chemotactic activity of defensins from human neutrophils”,J. Clin. Invest” 1989, vol,84, p.2017 ; Lillard,J.W·, 5 Jr.,Boyaka,P.N·,Chertov 0· et a]., “Mechanisms for induction of
acquired host immunity by neutrophil peptide defensins’’,Proc. Natl. Acad. Sci. U.S.A., 1999,vol.96, p.651 ;長岡功等、 「Defensin在感染防禦與免疫應答之角色」、臨床免疫、2000 年、第33卷、第577頁)。 10 目前為止,已知炎症性細胞介素或脂多醣具有促進人類/3 防禦素分泌之作用。然而,關於人類/3防禦素之產生、分泌之 機制’仍未能充分清楚解釋,且除上述物質以外,亦未知可促 進人類/3防禦素分泌之方法機制。 【發明内容】
15 因此,本發明之目的係提供可促進人類万防禦素分泌之yS
防紫素分泌促進劑。又,本發明之目的在於提供可以外用劑、 内用劑、食品等各種型態來使用之人類冷防禦素分泌促進劑。 又’本發明之目的是提供可有效促進人類万防禦素分泌之 方法。 20 本發明人為了解決上述課題而專心研討,結果發現,有機 酸具有可促進人類/3防禦素分泌之作用。本發明即是以該發現 為基礎再經過反覆研究而開發者。 亦即’本發明是以下揭示之人類冷防禦素分泌促進劑: 種人類/3防禦素分泌促進劑,係以有機酸為有效成分。 6 1342773 2.如第1項之人類/3防禦素分泌促進劑,其中前述有機酸 為選自於由延胡索酸、蘋果酸、檸檬酸、抗壞血酸、乳酸、醋 酸、己二酸、酒石酸、桂皮酸、麩胺酸及琥珀酸構成之群之至 少-種。 5 3.如第1項之人類yS防禦素分泌促進劑,其中前述有機酸 為選自於由延胡索酸、蘋果酸、檸檬酸及酒石酸構成之群之至 少一種。
4.如第1項之人類沒防禦素分泌促進劑,其中作為分泌促 進對象之人類/3防禦素為人類/3防禦素-2。 10 5.如第1項之人類yS防禦素分泌促進劑,係使用於口唇部 或口腔内。 6. —種人類防禦素分泌促進用之外用組成物,含有第1〜4 項中任一項之人類/5防禦素分泌促進劑。 7. —種人類/3防禦素分泌促進用之内用組成物,含有第1〜4 15 項中任一項之人類/3防禦素分泌促進劑。
8. —種人類;5防禦素分泌促進用之食品,含有第1〜4項中 任一項之人類/3防禦素分泌促進劑。 又,本發明是以下揭示之人類/3防禦素分泌促進方法: 9. 一種人類/3防禦素分泌促進方法,係對對象投予有效量 20 之有機酸或使對象攝取有效量之有機酸。 10. 如第9項之人類万防禦素分泌促進方法,其中前述有機 酸為選自於由延胡索酸、蘋果酸、檸檬酸、抗壞血酸、乳酸、 醋酸、己二酸、酒石酸、桂皮酸、麩胺酸及琥珀酸構成之群之 至少一種。 7 5 峻為Ζ第9項之人師防Μ分泌促進方法,其巾前述有機 Μ自於由延胡索酸、頻果酸、檸檬酸及酒石酸之 至少一種。 △如第9項之人類緒紫素分泌促進方法其中作為分泌 促進對象之人類㈣«為人類錄紫素-2。 13·如第9項之人㈣防禦素分泌促進方法,係在口 |部或 口腔内促進人類Θ防禦素分泌。 10 15
jl4.如第9項之人類万防禦素分泌促進方法,係使用第1〜5 具中任-項之人類0 P㈣素分泌促進劑作為前述有機酸。 15. 如第9項之人類諸禦素分泌促進方法係使用第6項 之内用組成物作為前述有機酸。 16. 如第9項之人類沒防禦素分泌促進方法,係使用第7項 之食品作為前述有機酸。 Π.如第9項之人類沒防禦素分泌促進方法,係使用第名 項之外用組成物作為前述有機酸。 又’本發明是以下使用態樣··
18.—種有機酸之用途,係用以製造人類石防禦素分泌促進 19. 一種有機酸之用途,係用以製造人類点防禦素分泌促進 20用内用組成物。 20. —種有機酸之用途,係用以製造人類点防禦素分泌促進 用食品。 21. —種有機酸之用途,係用以製造人類冷防禦素分泌促進 用外用組成物。 8 1342773 22.—種有機酸之用途,係用以促進人類冷防禦素之分泌。 圖式簡單說明 第1圖是顯示試驗例1中,於口腔内使用各有機酸時’唾 液中業經促進分泌之人類沒防禦素·2之量(ng/min)之圖。 5 第2圖是顯示試驗例2中,於口腔内使用各有機酸時,唾 液中業經促進分泌之人類冷防禦素·2之量(ng/min)之圖。 第3圖是顯示試驗例3中,於口腔内使用各種量之蘋果酸 時,唾液中業經促進分泌之人類厶防紫素-2之量(ng/min)之 圖。 10【實施方式】 用以實施發明之形態 (1)人類召防禦素分泌促進劑 本發明之人類万防禦素分泌促進劑中,作為分泌促進對象 之人類石防禦素中,包含了人類石防禦素_丨、人類防禦素-2、 15人類点防禦素_3、人類沒防禦素-4 '人類;5防禦素-5及人類/5 防禦素-6任一種。其中,尤其可有效促進人類沒防禦素_2之分 泌’因此成為最適當之分泌促進對象。 本發明之沒防禦素分泌促進劑之有效成分為有機酸。本發 明中所使用之有機酸,只要是藥學上、香粧學上或食品衛生上 2〇可容許者,皆無特別限制。本發明所使用之有機酸之一例,可 舉蟻酸、醋酸、丙酸、酪酸、纈草酸、己酸、辛酸、癸酸、月 桂酸、肉菫蔻酸、棕櫚酸、硬脂醆、丙烯酸、丙醯酸、桂皮酸、 咖啡酸等單羧酸;草酸、丙二酸、琥珀酸、麩酸、己二酸、庚 —酸、延胡索酸、順丁烯二酸、笨二甲酸、異笨二甲酸、對笨 9 1342773 二甲酸等二羧酸;麩胺酸、天冬胺酸等胺基酸;乙二醇酸、蘋 果酸、酒石酸、異酒石酸、#檬酸、異檸檬酸、乳酸、羥丙烯 酸、α-羥酪酸、丙三醇酸、羥基丙二醆、水楊酸、五倍子酸、 托品酸、抗壞血酸、葡糖酸等羥醆;葉酸;泛酸、菸鹼酸; 5及其他糖衍生物等之有機酸。其中又以延胡索酸、蘋果酸、 棒檬酸、抗壞血酸、乳酸、醋酸、己二酸、酒石酸、桂皮酸、 麵胺酸及琥珀酸為佳,更以延胡索睃、蘋果酸、檸檬酸及酒石 酸為佳。這些有機酸可單獨使用1種,或任意組合2種以上來 使用。又,本發明中,有效成分除上述有機酸外,還可使用藥 10學上、香粧學上或食品衛生上可容許之上述有機酸之鹽,或使 其鹽與上述有機酸結合。 八,丄逆3风敬便用褙裂者,只要含有上述有機 作為成分之-者,即可作為本發明之人師防禦素分泌促违 之有效成分來使用。 15 20
本發明之人㈣防《分崎進射以是由上述有效
分形成者,而除上述有效齡外,亦可含有其他食品衛生上 樂學上或隸學上可料之基劑、賴或添加物等其他成份 本發明之人類沒防禦素分泌促進劑之適用對象,並無特 限制,可以是活體内之任一部位或 ^ ^從較優異之人類 -素之分泌促進這個觀點來看’鼻腔内、肚門部、氣管内、 =、口腔内、咽頭、眼睛、生殖器、皮廣、消化器官内等 較適宜之對象。其中,在口唇部及口 促U 腔仅人類錄禦素分 從進作用特別優異,因此口唇部及 御ι 腔邛為本發明之人類/3 π素分泌促進劑之最適宜之適用對象。 10 1342773 本發明之人類万防紫素分泌促進劑可混合於食品、内用醫 藥品、内用醫藥部外品等,作為人類万防紫素分泌促進用之食 品或内用組成物來使用。又,本發明之人類績紫素分泌促進 劑,可混合於外用醫藥品、外用醫藥部外品、香粧品、外用品 5 (絆創膏)等,作从㈣防紫素分泌促進用之外用組成物來 使用。 含有本發明之人類Μ禦素分泌促進劑之人歸防” 分泌促進用外用組成物之調製,除上述有效成分外’還可混合 藥學上或香粧學上可容許之基劑或載趙,調製成所希望之形態 10即可。又’該外用組成物中,在不損壞本發明之效果之範圍内, 可混合各種界面活性劑、色素(染料、顏料)、香料、防腐劑、 殺菌劑(抗菌劑)、增稠劑、抗氧化劑、金屬堵劑、清涼化劑、 防臭劑、pH調整劑等各種添加劑。又,亦可因應需要添加保 濕劑、紫外線吸收劑、紫外線漫射劑、維他命類、植物精華液、 15皮膚收斂劑、抗炎症劑(消炎劑)、美白劑、細胞賦活劑、血 管擴張劑、血行促進劑、抗生素劑等可混合於外用劑之眾所周 知之藥效成分。 上述外用組成物,只要可使用於皮膚或黏膜,其形狀並無 特別限制,例如可舉液狀、乳液狀、粉末狀、懸浮液狀霜狀、 2〇軟膏狀、幕斯狀、膠狀、抹醬狀、糊狀、凍狀、片狀、噴霧狀、 噴淋狀、濃稠劑、面膜劑、貼附劑等形狀。又,上述外用組成 物之形狀可因應投予對象部位來適宜設定。 又,上述外用組成物只要以發揮人類点防禦素之分泌促進 作用為限度,亦可為具有人類点防禦素分泌促進作用以外之作 11 1342773 用之外用組成物、具體來說,可舉創傷治癒劑、輕拭劑、清淨 劑(例如洗顏料、洗面乳' 身體洗淨料等)、基礎化妝料(例 如乳液、乳霜、化妝水、油及面膜等)、刷牙劑、洗口劑、口 中清涼劑、口中用貼附劑等形態之外用組成物。尤其是從適用 5 於口腔内而可發揮人類yS防禦素分泌促進作用之觀點來看,以 口中用貼附劑、刷牙劑、洗口劑或口中清涼劑之形態為佳。
又,上述外用組成物亦可為浣腸製劑、點眼劑、點鼻劑等 形態。又,使用蒸散性有機酸作為人類/5防禦素分泌促進劑之 有效成分時,藉由使有效成分揮發(蒸發)並吸取,亦可適用 10 於鼻腔内、口腔内或支氣管内。以這種形態來使用之方法,可 舉例如將含有有效成分之水溶液加熱等,吸取所得到之蒸氣這 種方法。亦可以如此使有效成分蒸發來使用之形態調製上述外 用組成物。調製為這種形態時,上述外用組成物可因應需要, 藉由含有芳香成分,作為芳香液來使用。作為人類召防禦素分 15 泌促進劑之有效成分來使用之蒸散性有機酸可舉例如醋酸、丙 酸、蟻酸、酪酸、纈草酸等。 上述人類/3防禦素分泌促進用之外用組成物中之上述人類 /3防禦素分泌促進劑之混合比例,可因應該組成物之形態、有 效成分之種類、對象者之年齡或性別、所期待之效果等來適宜 20 地設定。例如,相對於上述外用組成物之總重量,上述人類/3 防禦素分泌促進劑之有效成分之比例可舉以總量0.001重量% 以上為佳,又以0.005〜99重量%為佳,又以0.01〜99重量%更佳。 本發明之人類/3防禦素分泌促進劑藉由使用於皮膚或黏 膜,可發揮人類/5防禦素分泌促進作用。使用該人類/3防禦素 12 1342773 分泌促進劑之量及次數,可因應有效成分之種類或濃度、使用 者之年齡或性別、使用形態、所期待之程度等來適宜地設定。 例如,以一日1〜10次之程度,於皮膚或黏膜使用人類/3防禦素 分泌促進劑之有效成分O.lmg以上,又以0.5〜lOOOOmg為佳。 5 又,調製含有本發明之人類点防禦素分泌促進劑之人類/3
防禦素分泌促進作用之食品時,在一般之食品製造中,以上述 有效成分為成分之一混合於食品(包含飲料)中即可。又,人 類/5防禦素分泌促進用食品中,可適當含有食品衛生上可容許 之各種食品添加物。 10 上述食品可舉例如特定保徤用食品、營養補助食品、病患
用食品等。更具體來說,可例舉飲料(碳酸飲料、清涼飲料、 乳飲料、酒精飲料、果汁飲料、茶類、營養飲料等)、粉末飲 料(粉末果汁、粉末湯等)、點心類(口香糖、糖果、餅乾、 膠質點心、仙貝、比斯吉、果凍、牛奶糖、檸檬劑糖、可食性 15 片材、可食性薄片、喉錠等)、口中清涼劑(口香糖、飴、膠 質點心、可食性片材、可食性薄片、喉錠等)、乳製品(乳酪、 優格等)、麵包、麵類、五榖、調味料(醬汁、調味汁等)等。 從促進口腔内人類yS防禦素之分泌這個觀點來看,其中適宜的 可有口香糖、膠質點心、檸檬劑、糖果、可食性片材及可食性 20 薄片。 上述人類/3防禦素分泌促進用食品中,所混合之人類/3防 禦素分泌促進劑之比例,可因應有效成分之種類、對象者之年 齡、性別、所期待之效果等來適宜地設定。例如,相對於上述 食品之總重量,上述人類;5防禦素分泌促進劑之有效成分之比 13 1342773 例可舉以總量0.01重量%以上為佳,又以〇〇2〜1〇〇重量%為佳 又以0.05〜100重量%更佳。 關於上述人類点防禦素分泌促進用食品—日之攝取量。 因應有效成分之種類或濃度、使用者之年齡或性别、食品之^ 5態、所㈣之效果,來適宜地設枝進人類諸紫素分泌所冑 · 要之有效量。例如,該食品-曰之攝取量,可舉人類卢防紫素 . 分泌促進劑之有效成分o.lmg以上,又以〇5〜1〇〇〇〇mg之I為 佳。 .、 又,調製含有本發明之人類/3防禦素分泌促進劑之人類点 · 1〇防禦素分泌促進作用之内用醫藥品組成物或内用醫藥部外品 組成物時,除上述有效成分之外,再混合藥學上可容許之基劑 或載體,調製成所希望之形態即可。又,可因應需要任意配合 結合劑、崩解劑' 滑澤劑、濕澗化劑、緩衝劑、保存劑、香料 等藥學上可容許之添加劑。 上述内用醫藥品組成物或内用醫藥部外品組成物之形態, 並無特別限制,不過宜為可在黏膜上、特別是口香内熔解者。 $ 例如,可舉薄片劑、喉錠、咀嚼錠、粉劑、錠劑、顆粒劑、膠 囊劑、糖漿劑等。其申,從可在口腔内熔解這個觀點來看,以 舉薄片劑、喉錠及咀嚼錠為佳。 )〇 > 關於上述内用醫藥品或内用醫藥部外品組成物中,人類冷 防禦素分泌促進劑之混合比例,可因應有效成分之種類、組成 物之形態、對象者之年齡或性別、所期待之效果等來適宜地設 疋。例如,相對於上述内用醫藥品或内用醫藥部外品組成物之 總重量’上述人類点防禦素分泌促進劑之有效成分之比例為總 14 1342773 量0.01重量%以上為佳,又以0.02〜99重量%為佳,又以0.05〜99 重量%更佳。
關於上述内用醫藥品或内用醫藥部外品組成物人類之一曰 之投藥量,會隨著有效成分之種類或濃度、使用者之年齡或性 5 別、組成物之形狀、投藥方法、所期待之程度等而不同,因此 不能統一規定。不過只要是可促進人類/3防禦素分泌之有效量 即可。例如,一曰投藥1〜1〇次,每一次之投藥量為人類召防禦 素分泌促進劑之有效成分O.lmg以上,又以0.5〜lOOOOmg之量為 佳。 10 如前所述,有機酸具有促進人類/3防禦素分泌之作用。因 此,本發明更提供有機酸之用於製造人類^防禦素分泌促進用 之外用組成物或内用組成物之用途。 (2)人類卢防禦素分泌促進方法 如前所述,有機酸可有效促進人類/3防禦素之分泌。因此, 15 本發明提供利用有機酸促進人類/3防禦素之分泌之方法。
本發明之人類点防禦素分泌促進方法,係藉由針對目的欲 促進人類/5防禦素分泌之身體部位以外用形態投予有機酸來 實施。又,本發明之人類/3防禦素分泌促進方法可藉由以内用 形態投予有機酸,或使對象攝取有機酸來實施。本發明之方法 20 係藉由使用上述(1 )之人類/3防禦素分泌促進劑、尤其是人 類/3防禦素分泌促進用之外用組成物、内用組成物或食品來實 施。 本發明方法中,被促進分泌之人類/5防禦素、使用之有機 酸、該有機酸之投藥量或投藥次數、作為分泌促進對象之身體 15 1342773 部位(或組織)等,如前(1 )所記載。 藉由使用有機酸,可有效促進人類yS防禦素之分泌。因此, 本發明更是提供有機酸之用以促進人類/3防禦素分泌之用途。 (3)人類石防禦素分泌促進方法-2 5 又,本發明人發現,藉由使口腔内環境暫時呈現酸性,即
可促進口腔内之人類/3防禦素分泌。依據該發現,本發明更提 供促進口腔内人類点防禦素分泌之方法。藉該方法,欲促進人 類/3防禦素分泌,
口腔内環境暫時呈現酸性,具體來說使口腔内之pH保持在7 10 以下即可,又以6.2以下為佳。又,該方法中,使口腔内環境保 持酸性之時間,是促進人類/3防禦素分泌之有效時間即可。 又,該方法中,欲使口腔内環境成為酸性,例如只需在口腔内 投予前述有機酸即可。該方法之適當實施形態之一例,可舉在 口腔内投予前述人類/3防禦素分泌促進劑之方法。藉該方法,· 15 可保持口腔内健康,因此,該方法對預防及緩和牙周病、口内 炎、齟齒、口臭等是有用的。 又,上述(1 )之人類yS防禦素分泌促進劑之用途、或上述 (2)之人類/3防禦素分泌促進方法中,皮膚或黏膜上之pH條 件並無特別限制。 20 實施例 以下舉實施例及試驗例說明本發明,然而本發明並不受限 於這些實施例。又,以下,人類/3防禦素亦僅表記為hBD-2。 實施例1 口香糖 依據一般方法製造下述處方之口香糖。 16 1342773 混合量(重量%) 檸檬粉末 5.0 (檸檬粉末中含檸檬酸75重量%) 口香糖基質(主成分:醋酸乙烯) 22.0 木糖醇 35.0 麥芽糖醇 27.0 香料 適量 合計 100重量% 實施例2 檸檬劑糖果
依據一般方法製造下述處方之檸檬劑糖果。 混合量(重量% ) 蘋果酸 碳酸氫鈉 木糖醇 麥芽糖醇 玉米澱粉 合計 7.5 7.5 40.0 30.0 15.0 100重量% 實施例3 口中清涼錠(液狀) 依據一般方法製造下述處方之口中清涼錠(液狀)。 乳酸 混合量(重量%) 0.2 1 -薄荷醇 1.0 乙醇 40.0 丙三醇 20.0 單月桂酸十丙三醇 0.5 香料 0.1 精製水 殘量 合計 100重量% 實施例4 口中清涼錠 (喉錠)
10 依據一般方法製造下述處方之口中清涼錠(喉錠)。 17 1342773 酒石酸 1 -薄荷醇 碳酸氫鈉 乳糖 蔗糖脂肪酸酯 風味劑 甘味劑 合計 混合量(重量%) 45 1 24 25 3 1 1 100重量% 實施例5 食品(喉錠) 依據一般方法製造下述處方之食品(喉錠)。
抗壞血酸 乳糖 木糖醇 蔗糖脂肪酸酯 風味劑 合計 混合量(重量%) 5.0 85.5 5.0 4.0 0.5 100重量% 實施例6 液體刷牙劑 依據一般方法製造下述處方之液體刷牙劑。
延胡索酸 1-薄荷醇 碳酸氫鈉 混合量(重量%) 45 1 24 乳糖 25 蔗糖脂肪酸酯 3 風味劑 1 甘味劑 1 合計 100重量% 實施例7 芳香液 10 依據一般方法製造下述處方之芳香液。 18 1342773 精製水 無水乙醇 檸檬萃取 葡萄柚萃取 醋酸 香料 合計 混合量(重量%) 54 40 4 1 1 適量 100重量% 實施例8 點鼻劑
依據一般方法製造下述處方之點鼻劑。 成分名 混合量(重量%) 氣化鈉 0.9 檸檬酸 1.0 pH調整劑 精製水 合計 適量 殘餘 100重量% 實施例9 點眼劑 依據一般方法製造下述處方之點眼劑。
成分名 氣化納 氣化鉀 黃素腺二核苷酸 透明質酸 擰檬酸 pH調整劑 精製水 合計 混合量(重量%) 0.9 0.1 0.05 0.1 1.0 適量 殘餘 100重量% 試驗例1 yS防禦素分泌促進確認試驗-1 10 為了評價各種有機酸之yS防禦素分泌促進效果,以健常人1 名為受驗者進行下述試驗。 19 1342773
藉吐出法回收業已處於安靜之受驗者在3分鐘内所分泌之 唾液(以下記為控制組)。然後,於口腔内放入延胡索酸50mg, 保持1分鐘後,與分泌出之唾液一起回收。藉ELISA法,測定所 回收之唾液中之人類yS防禦素-2濃度,依據下記計算式,計算 5 出在1分鐘内藉該有機酸而分泌之人類/3防禦素-2之量。但是, 下記計算式中之01液量(ml )係以唾液重量1 g=唾液量1 ml,而 從業已回收之唾液之重量(g)算出。前述相同試驗,亦分別 利用抗壞血酸、檸檬酸、蘋果酸、乳酸、己二酸、醋酸及酒石 酸取代延胡索酸來進行。又,乳酸及醋酸之情況,係藉由在口 10 腔中置入業已在該有機酸50mg中添加水以調整全量為lg者,來 進行上述試驗。 計算式 [1分錢被分泌之hBD-2之量(ng/min)]= {[唾液中之hBD-2濃度(ng/ml)] X [唾液量(ml)]}/[°t液回收時間(min)] 15 #唾液回收時間,在控制組為3分鐘,在投予有機酸後之情況為1分鐘。
所得到之結果顯示於第1圖。可清楚得知,藉由在口腔内適 用有機酸,而增加了唾液中所分泌之人類yS防禦素-2量。從該 結果,確認了有機酸具有促進活體内人類点防禦素-2之分泌之 作用,尤其在口腔内之人類/3防禦素-2之分泌促進作用上很優 20 異。 試驗例2 yS防禦素分泌促進確認試驗-2 為了評價各種有機酸之/5防禦素分泌促進效果,以健常人6 名為受驗者進行下述試驗。有機酸係使用檸檬酸、蘋果酸、延 胡索酸、L-麩胺酸、反桂皮酸、L ( + )-抗壞血酸、琥珀酸、 20 1342773 DL·-酒石酸、己二酸、L·-乳酸及醋酸。
藉吐出法回收業已處於安靜之受驗者在3分鐘内所分泌之 唾液(以下記為控制組)。然後,於口腔内放入有機酸50mg ’ 保持1分鐘後,與分泌出之唾液一起回收。藉ELISA法,測定所 5 回收之唾液中之人類/3防禦素-2濃度,依據下記計算式,計算 出在1分鐘内藉該有機酸而分泌之人類/3防禦素-2之量。但是, 下記計算式中之唾液量(ml )係以唾液重量1 g=唾液量1 ml,而 從業已回收之唾液之重量(g)算出。又,乳酸及醋酸之情況, 係藉由在口腔中置入業已在該有機酸50mg中添加水以調整全 10 量為lg者,來進行上述試驗。 計算式 [1分錢被分泌之hBD-2之量(ng/min)]= {[唾液中之hBD-2濃度(ng/ml)] X [唾液量(ml)]}/[唾液回收時間(min)] #唾液回收時間,在控制組為3分鐘,在投予有機酸後之情況為1分鐘。 15 所得到之結果顯示於第2圖。從該結果可清楚得知,與試驗
例1之結果同樣地,藉由在口腔内適用有機酸,而增加了唾液 中所分泌之人類/3防禦素-2量。 試驗例3 沒防禦素分泌促進確認試驗-3 (濃度依賴性) 為了評價有機酸之万防禦素分泌促進效果與濃度依賴性之 20 關係,以健常人3名為受驗者進行下述試驗。 藉吐出法回收業已處於安靜之受驗者在3分鐘内所分泌之 唾液(以下記為控制組)。然後,於口腔内放入0.01重量%蘋果 酸水溶液1 ml (蘋果酸攝取量0.1 mg )。保持1分鐘後,與分泌出 之唾液一起回收。藉ELISA法,測定所回收之唾液中之人類/3 21 1342773 防禦素-2濃度,依據下記計算式,計算出在1分鐘内藉攝取該蘋 果酸而分泌之人類石防禦素_2之量。但是,下記計算式中之唾 液量(ml)係以咕液重量lg==唾液量lml,而從業已回收之唾液 之重量(g)算出。進一步,分別利用〇.〇5、0.1、0.2、0.5及1 5 重量%蘋果酸水溶液(攝取量〇.5、1、2、5、10mg)進行。 計算式 Π分鐘被分泌之hBD-2之量(ng/min)]= {["t液中之hBD·2濃度(ng/ml)] X [喷液量(ml)]}/[唾液回收時間(min)] #唾液回收時間’在控制組為3分錢,在投予有機酸後之情況為1分錢。 10 所得到之結果顯示於第3圖。從第3圖可清楚得知,唾液中 所分泌之人類沒防禦素-2量係蘋果酸水溶液之濃度依賴性而增 大。從該結果,確認了有機酸之人類防禦素·2分泌促進效果 具有濃度依賴性,即使為〇·〇1%濃度(攝取量0.lmg),也具有 人類万防禦素-2分泌衍生效果。 15 產業上可利用性 人類々防禦素因具備以下優異特性而為人所知:(a)由於 其自身具有抗菌性,因此可在短時間内發揮抗菌作用;(b)由 於在活體内分必,因此對習知抗菌劑難以利用外用或内用形熊 來投藥之部位,也可發揮優異抗菌作用:(c)使樹狀細胞或記 20憶T淋巴球趨化(chemotaxis)(亦即,動貞免疫負責細胞而與 後天免疫有關)。 本發明之人類点防禦素分泌促進劑可在適用之部位促進冷 防禦素之分泌,尤其是促進人類点防禦素_2之分泌。因此,藉 本發明之人類/3防禦素分泌促進劑,可促進点防禦素之分泌’ 22 1342773 增強活體内之抗菌作用或免疫作用,藉此,可提高活體之防禦 機制。因此,本發明之人類以方紫素分泌促進劑對預防或緩和 起因於細菌、真菌、病毒、原蟲感染所造成之症狀上很有效。 尤其是可有效利用在預防異位性皮廣炎之二次感染、預防面皰 5粉刺、防止口臭、防止足臭、預防到鬚或脫毛後之二次感染、 預防尿布疹之二次感染、預防痱子之二次感染、預防燙傷之二 次感染、預防因使用類固醇造成之易感染性等護膚上。又,對 起因於細菌、真菌、病毒、原蟲感染所造成之皮廣粗糖、皮廣 乾燥、富貴手等護廣上也有效。 10 又,本發明之人類点防禦素分泌促進劑,可期待其依據人 類;5防禦素分泌促進作用所帶來的藥理效果。因此,本發明之 人類/5防禦素分泌促進劑,例如投藥於眼内時,可預防或治療 病毒性結膜炎、細菌性結膜炎、麥粒腫等;投藥於鼻腔内或咽 頭時,可預防或治療感W、流行性感冒等:投藥於鼻腔内時, 15可預防或治療鼻炎、膿性鼻漏、副鼻腔炎等;使用於口腔内時, 可預防或治療牙周病、口内炎、齟齒等,使用於口唇部時,可 預防或治療單純泡疹等;使用於皮膚時,可預防香港腳治療 泡療、疢贅、傳染性軟屬腫、水痘、性器官泡療病毒感染症、 念珠菌症、帶狀泡m躲、面皰、異位性皮膚炎、創傷 20等;使用於其他部位時,可作為肺炎、胃炎 '腫瘤、後天性免 疫缺乏症、錐蟲病等疾病之預防或治療劑。這些疾病當中,作 為與細菌、真菌、病毒、原蟲等有關之疾病之預防或治療劑尤 其有用。 又,本發明之人類沒防禦素分泌促進劑,在口腔内及口唇 23 1342773 部可發揮進一步的/S防禦素分泌促進作用,因此作為牙周病、 口内炎、齟齒、口臭、單純泡疹等之預防或治療劑特別有效。 因此,本發明之人類yS防禦素分泌促進劑可適當使用在用以保 持健康口腔環境之護膚製品。 5【圖式簡單說明】 第1圖是顯示試驗例1中,於口腔内使用各有機酸時,唾 液中業經促進分泌之人類/3防禦素-2之量(ng/min)之圖。 第2圖是顯示試驗例2中,於口腔内使用各有機酸時,唾 液中業經促進分泌之人類/3防禦素-2之量(ng/min)之圖。 10 第3圖是顯示試驗例3中,於口腔内使用各種量之蘋果酸 時,唾液中業經促進分泌之人類/5防禦素-2之量(ng/min )之 圖。 【主要元件符號說明】 無
24
Claims (1)
1342773 公告本 5 10 15 忉年Ιί月?曰修(更)正本 第93丨28401號專利申請案申請專利範圍替換本 卯年u」十、申請專利範圍: 1· 一種人_防紫素分泌促進劑’其特徵在於·以選自於由 延胡索酸、蘋果酸、檸檬酸、抗壞血酸、乳酸、醋酸、己 二醆、酒石酸、桂皮醆、麩胺酸及_賴構成群組令之 至少一種有機酸作為有效成分,且施用在口腔内而用以促 進人類汐防禦素在口腔内之分泌。 2. 如申請專利範圍第】項之人類点防紫素分泌促進劑其中前 述有機酸選自於由延胡索醆、蘋果酸、擦樣酸及酒石酸所 構成群組中之至少一種。 3. 如申請專利範圍第!項之人類^防紫素分泌促進劑其中成 為分泌促進對象之人類召防禦素為人類y?防禦素-2。 4- 一種人類厶防禦素分泌促進用之外用組成物,含有如申請 專利範圍第卜3項中任-項之人類㈣禦素分泌促進劑。 5. —種人類/3防禦素分泌促進用之内用組成物,含有如申請 專利範圍第卜3項中任-項之人類諸紫素分泌促進劑。 —種人類/3防禦素分泌促進用之食品,含有如申請專利範 圍第1 ~3項中任一項之人類厶防禦素分泌促進劑。 •一種人類/9防禦素分泌促進方法,係於非治療目的下,將 有效量之選自於由延胡索酸、蘋果酸、檸檬酸、抗壞血酸、 乳酸、醋酸、己二酸、酒石酸、桂皮酸、麩胺酸及琥珀酸 所構成群組中之至少一種有機酸投予至口腔内,以促進人 類/5防禦素在口腔内之分泌。 •如申請專利範圍第7項之人類点防禦素分泌促進方法,其中 前述有機酸選自於由延胡索酸、蘋果酸 '檸檬酸及酒石酸
25 所構成群組中之至少一種。 9.如申請專利範圍第7項之人_防禦素分泌促進方法,其中 成為分泌促進對象之人類召防禦素為人類沒防禦素_2。 〇.如申請專利範圍第7項之人類万防紫素分泌促進方法,其係 使用如申吻專利範圍第1 ~3項中任一項之人類沒防紫素分 &促進劑作為有機酸。 1·如申請專利範圍第7項之於口腔内的人類沒防紫素分泌促 進方法,其係使用如申請專利範圍第5項之内用組成物作為 有機酸。 2’如申靖專利範圍第7項之人類万防禦素分泌促進方法,其係 使用申請專利範圍第6項之食品作為前述有機酸。 13. 如申凊專利範圍第7項之人類々防禦素分泌促進方法,其係 使用申請專利範圍第4項之外用組成物作為前述有機酸。 14. 一種將有機酸使用在製造人類石防禦素分泌促進劑之用 途’該有機酸係選自於由延胡索酸、蘋果酸、檸樣酸、抗 壞血酸、乳酸、醋酸、己二酸、酒石酸、桂皮酸、麩胺酸 及琥珀酸所構成群組中之至少一種物質,且該人類万防禦 素分泌促進劑係施用口腔内而用以促進人類点防禦素在口 腔内之分泌。 15. —種將有機酸使用在製造人類点防禦素分泌促進用内用組 成物之用途’該有機酸係選自於由延胡索酸、蘋果酸、择 檬酸、抗壞血酸、乳酸、醋酸、己二酸、酒石酸、桂皮酸、 麩胺酸及琥珀酸所構成群組中之至少一種物質,且該人類 泠防禦素分泌促進用内用组成物係施用口腔内而用以促進 1342773
人類/5防禦素在口腔内之分泌。 16 · —種將有機酸使用在製造人類点防禦素分泌促進用食品之 用途,該有機酸係選自於由延胡索酸、蘋果酸、檸檬酸、 抗壞血酸、乳酸、醋酸、己二酸、酒石酸、桂皮酸、麩胺 5 酸及琥珀酸所構成群組中之至少一種物質,且該人類召防 禦素分泌促進用内用組成物係施用口腔内而用以促進人類 /3防禦素在口腔内之分泌。
17. —種於非治療目的下將有機酸用以促進人類/3防禦素在口 腔内之分泌的用途,且該有機酸係選自於由延胡索酸、蘋 10 果酸、檸檬酸、抗壞血酸、乳酸、醋酸、己二酸、酒石酸、 桂皮酸、麩胺酸及琥珀酸所構成群組中之至少一種物質。
27
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003328704 | 2003-09-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200524585A TW200524585A (en) | 2005-08-01 |
TWI342773B true TWI342773B (zh) | 2011-06-01 |
Family
ID=34372909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093128401A TW200524585A (en) | 2003-09-19 | 2004-09-20 | Human β-defensin secretion promoter |
Country Status (11)
Country | Link |
---|---|
US (1) | US20070093416A1 (zh) |
EP (1) | EP1671629A4 (zh) |
JP (1) | JP4847756B2 (zh) |
KR (1) | KR20060076775A (zh) |
CN (1) | CN1852708B (zh) |
AU (1) | AU2004273738B2 (zh) |
BR (1) | BRPI0414543A (zh) |
CA (1) | CA2538760A1 (zh) |
HK (1) | HK1092057A1 (zh) |
TW (1) | TW200524585A (zh) |
WO (1) | WO2005027893A1 (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090030281A (ko) | 2006-06-28 | 2009-03-24 | 오츠카 세이야쿠 가부시키가이샤 | 치아 에나멜질의 용해 저해제 |
JPWO2008096730A1 (ja) * | 2007-02-09 | 2010-05-20 | 国立大学法人名古屋大学 | 抗炎症剤及びその用途 |
JP2009007323A (ja) * | 2007-05-29 | 2009-01-15 | Earth Chem Corp Ltd | ウイルス不活化剤、ウイルス感染予防方法及びそのウイルス不活化剤をも収納し得る容器 |
JP5511183B2 (ja) * | 2007-12-28 | 2014-06-04 | アース製薬株式会社 | 有機酸による歯のエナメル質の溶解が阻害される口腔用組成物 |
US8076088B2 (en) * | 2008-02-22 | 2011-12-13 | Case Western Reserve University | Method of detecting human β-defensins |
KR101489638B1 (ko) * | 2008-04-01 | 2015-02-11 | (주)네오팜 | 인간유래 항균 펩타이드의 분비를 촉진하는 신규화합물, 그제조방법, 및 이를 유효성분으로 함유하는피부외용제조성물 |
CN101591672B (zh) * | 2009-05-22 | 2011-09-07 | 西北农林科技大学 | 一种包含hBD3乳腺特异性表达载体的重组牛胎儿成纤维细胞 |
GB0920846D0 (en) | 2009-11-27 | 2010-01-13 | Croda Int Plc | Defenin inducing agent |
NZ602909A (en) | 2010-04-15 | 2015-01-30 | Marinepolymer Tech Inc | Anti-bacterial applications of poly -n-acetylglucosamine nanofibers |
KR101257228B1 (ko) * | 2010-06-16 | 2013-04-29 | 주식회사 나이벡 | 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물 |
EP2617707B1 (en) | 2010-08-27 | 2016-10-05 | Neopharm Co., Ltd. | Novel compound accelerating secretion of human-derived anti-microbial peptide, method for preparing same, and composition having same as active ingredient |
CA2832859C (en) | 2011-04-15 | 2020-06-16 | Marine Polymer Technologies, Inc. | Treatment of disease with poly-n-acetylglucosamine nanofibers |
GEP20166431B (en) * | 2011-09-27 | 2016-02-10 | Santen Pharmaceutical Co Ltd | Inhibitor for corneal epithelial cell death, inhibitor characterized by combining hyaluronic acid and flavin adenine dinucleotide |
US9532946B2 (en) | 2012-11-20 | 2017-01-03 | Intervet Inc. | Manufacturing of semi-plastic pharmaceutical dosage units |
WO2014125977A1 (ja) * | 2013-02-14 | 2014-08-21 | ライオン株式会社 | 口腔用組成物 |
JP6209062B2 (ja) * | 2013-11-12 | 2017-10-04 | 株式会社ファンケル | 抗菌性ペプチドの分泌促進剤 |
EP3834615A1 (en) * | 2016-03-31 | 2021-06-16 | Gojo Industries, Inc. | Antimicrobial peptide stimulating sanitizing composition |
US10806769B2 (en) | 2016-03-31 | 2020-10-20 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
AU2017240069B2 (en) | 2016-03-31 | 2024-03-07 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
US11564879B2 (en) | 2016-11-23 | 2023-01-31 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
KR102488864B1 (ko) * | 2016-11-25 | 2023-01-17 | (주)모아캠 | 가자 추출물 및 애엽 추출물을 함유하는 피부세균총의 생장 조절 또는 피부 면역 강화용 조성물 |
CN107918010A (zh) * | 2017-11-27 | 2018-04-17 | 陕西科技大学 | 一种高灵敏液晶型非标记免疫传感器检测人类β防御素‑2的方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL58009A (en) * | 1978-08-14 | 1982-11-30 | Sterling Drug Inc | Process and compositions comprising glutaric acid for neutralizing or destroying viruses |
JPH03294227A (ja) * | 1990-04-13 | 1991-12-25 | Dai Ichi Seiyaku Co Ltd | 口腔用組成物 |
AU1271592A (en) * | 1991-01-18 | 1992-08-27 | Dexter Chemical Corporation | Malic acid derivatives and compositions for the treatment of psoriasis |
US5260083A (en) * | 1992-03-25 | 1993-11-09 | The J. M. Smucker Company | Fruit spread and method of preparing same |
JP3207523B2 (ja) * | 1992-06-19 | 2001-09-10 | 明治乳業株式会社 | 肝障害患者に有効な組成物 |
CN1033421C (zh) * | 1992-12-09 | 1996-12-04 | 何名富 | 一种药物牙膏的制备方法 |
US5830487A (en) * | 1996-06-05 | 1998-11-03 | The Procter & Gamble Company | Anti-viral, anhydrous, and mild skin lotions for application to tissue paper products |
DE4439858A1 (de) * | 1994-11-08 | 1996-05-09 | Merck Patent Gmbh | Durch Co-Sprühtrocknung erhältliche Polyol-Zusammensetzung |
JP3241955B2 (ja) * | 1994-12-26 | 2001-12-25 | 花王株式会社 | 口腔用組成物 |
WO1996026707A1 (en) * | 1995-02-28 | 1996-09-06 | U.S. Meds - Bulgaria Ltd. | Composition for hygiene, prophylaxis and treatment of the oral cavity |
CN1229641A (zh) * | 1998-03-20 | 1999-09-29 | 湖北医科大学附属第二医院 | 假牙清洁剂 |
US6469066B1 (en) * | 1998-12-18 | 2002-10-22 | Palladin Healthcare International, Ltd. | Composition for pain mediation and apparatus and method of use thereof |
JP2001089385A (ja) * | 1999-09-22 | 2001-04-03 | Kobayashi Pharmaceut Co Ltd | 抗う蝕剤 |
TR200201048T2 (tr) * | 1999-10-19 | 2002-08-21 | The Procter & Gamble Company | Soğuk algınlığı ve gribi andıran semptomların önlenmesi ve tedavisi için bileşimler |
AU2001245726A1 (en) * | 2000-03-15 | 2001-09-24 | Genaera Corporation | A method for stimulation of defensin production |
JP2002114704A (ja) * | 2000-09-29 | 2002-04-16 | Morinaga & Co Ltd | 抗菌剤 |
JP2003000262A (ja) * | 2001-06-22 | 2003-01-07 | Morinaga & Co Ltd | ほ乳類抗菌ペプチドの発現誘導及び/又は増強組成物、該組成物を含有する飲食品、医薬品及び医薬部外品 |
JP2003116486A (ja) * | 2001-08-09 | 2003-04-22 | Meiji Milk Prod Co Ltd | 食後の血糖上昇抑制作用を有する食品組成物 |
JP2003095938A (ja) * | 2001-09-21 | 2003-04-03 | Masami Moriyama | 抗菌ペプチド分泌誘発剤 |
US20040063123A1 (en) * | 2002-03-05 | 2004-04-01 | Yoshihiro Abiko | Method of collecting data for estimation of susceptibility to periodontal disease |
FR2843125B1 (fr) * | 2002-08-02 | 2012-11-16 | Coletica | Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs |
JP4554150B2 (ja) * | 2002-11-28 | 2010-09-29 | 雅美 森山 | 薬剤耐性菌による感染症治療剤 |
JP4683844B2 (ja) * | 2003-02-10 | 2011-05-18 | 雅美 森山 | インフルエンザウイルス感染予防剤 |
US7041311B2 (en) * | 2003-02-28 | 2006-05-09 | International Flavors & Fragrances Inc. | Preparation for saliva flow |
-
2004
- 2004-09-17 CN CN2004800270414A patent/CN1852708B/zh not_active Expired - Fee Related
- 2004-09-17 KR KR1020067005330A patent/KR20060076775A/ko not_active Application Discontinuation
- 2004-09-17 CA CA002538760A patent/CA2538760A1/en not_active Abandoned
- 2004-09-17 WO PCT/JP2004/014024 patent/WO2005027893A1/ja active Application Filing
- 2004-09-17 AU AU2004273738A patent/AU2004273738B2/en not_active Ceased
- 2004-09-17 JP JP2005514130A patent/JP4847756B2/ja active Active
- 2004-09-17 BR BRPI0414543-7A patent/BRPI0414543A/pt not_active IP Right Cessation
- 2004-09-17 EP EP04773408A patent/EP1671629A4/en not_active Withdrawn
- 2004-09-17 US US10/572,204 patent/US20070093416A1/en not_active Abandoned
- 2004-09-20 TW TW093128401A patent/TW200524585A/zh not_active IP Right Cessation
-
2006
- 2006-11-20 HK HK06112727.9A patent/HK1092057A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HK1092057A1 (en) | 2007-02-02 |
JP4847756B2 (ja) | 2011-12-28 |
EP1671629A1 (en) | 2006-06-21 |
KR20060076775A (ko) | 2006-07-04 |
AU2004273738A1 (en) | 2005-03-31 |
EP1671629A4 (en) | 2008-11-26 |
AU2004273738B2 (en) | 2011-02-03 |
TW200524585A (en) | 2005-08-01 |
BRPI0414543A (pt) | 2006-11-07 |
CN1852708A (zh) | 2006-10-25 |
CN1852708B (zh) | 2010-09-22 |
CA2538760A1 (en) | 2005-03-31 |
US20070093416A1 (en) | 2007-04-26 |
JPWO2005027893A1 (ja) | 2006-11-24 |
WO2005027893A1 (ja) | 2005-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI342773B (zh) | ||
EP2155222B1 (en) | Extract of trigonella foenum-graecum | |
TW200533333A (en) | Human beta-defensin production accelerator | |
CN108670889A (zh) | 一种防治口腔溃疡的牙膏及其制备方法 | |
RU2762754C2 (ru) | Композиция для применения в предупреждении и/или лечении индуцированного онкологическим лечением мукозита полости рта и желудочно-кишечного тракта | |
JPH08325156A (ja) | ステビオール配糖体含有皮膚外用剤及び飲食品 | |
US20040214750A1 (en) | Medicaments for healing skin conditions in humans | |
JP6600124B2 (ja) | 菓子 | |
JP5328158B2 (ja) | カンジダ菌感染に基づく疾患の予防又は改善剤及び経口組成物 | |
JP6256770B2 (ja) | 口腔ケア組成物、錠剤、顆粒状薬剤 | |
JP2023038290A (ja) | ロイシン誘導体、それを含む組成物及びその用途 | |
JP6021005B2 (ja) | 抗菌組成物およびその利用 | |
JP2009051770A (ja) | 食欲抑制用組成物 | |
JP2007031302A (ja) | アディポネクチン産生促進剤、及び代謝異常症候群予防剤 | |
US20220023426A1 (en) | Oral mucosal carrier and protectant | |
JPH08133983A (ja) | アスパラス・リネアリス抽出物及び用途 | |
JP3560424B2 (ja) | 抗菌性組成物 | |
AU2021225354B2 (en) | Composition for the prevention and treatment of dysbiosis | |
RU2777153C1 (ru) | Композиция для ухода за полостью рта для пациентов с метаболическими нарушениями | |
US20230041103A1 (en) | Composition for the prevention and treatment of dysbiosis | |
WO2006003750A1 (ja) | 炎症予防・抗炎症剤、医薬品、飲食品及び香粧品 | |
JP2022099508A (ja) | 殺コロナウイルス剤 | |
JP2022057767A (ja) | 殺コロナウイルス剤 | |
WO2004009105A1 (en) | Phytotherapic composition based on vegetable extracts, process for obtainment of said composition and use of vegetable extracts for preparation of a phytotherapic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |